Xtant Medical Holdings (XTNT) AI Stock Analysis

• Market Cap: $103.88M
• Dividend Yield: N/A
• Average Volume (3M): 184.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.18
• Revenue Growth: 15.16%
• EPS Growth: -39.18%
• Country: US
• Employees: 217
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.09
• Shares Outstanding: 140,000,490
• 10 Day Avg. Volume: 355,541
• 30 Day Avg. Volume: 184,719
• PEG Ratio: <0.01
• Price to Book (P/B): 1.38
• Price to Sales (P/S): 0.50
• P/FCF Ratio: -3.70
• Enterprise Value/Market Cap: 1.35
• Enterprise Value/Revenue: 1.09
• Enterprise Value/Gross Profit: 1.82
• Enterprise Value/Ebitda: 30.65
• 1Y Price Target: $2.00
• Price Target Upside: 166.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $1.00 ▲(33.33% Upside)

Xtant Medical Holdings' overall score is driven by strong earnings call results, indicating significant revenue growth and improved profitability. However, financial performance challenges and a weak valuation score due to negative P/E ratio weigh down the overall score. Technical analysis provides a positive outlook with strong market momentum.

Positive Factors

Revenue Growth

The strong revenue growth of 18% YoY indicates robust demand for Xtant's products, suggesting effective market penetration and product adoption, which is crucial for long-term business sustainability.

Gross Margin Improvement

Improved gross margins reflect better cost management and production efficiency, enhancing profitability potential and providing a buffer against cost fluctuations.

Product Portfolio Expansion

The launch of new products strengthens Xtant's competitive position in the biologics segment, driving future revenue growth and market share expansion.

Negative Factors

Profitability Challenges

Ongoing profitability issues, indicated by negative net margins, could hinder reinvestment in growth initiatives and affect long-term financial health.

Cash Flow Constraints

Limited cash generation from operations restricts the company's ability to fund new projects or manage debt, impacting financial flexibility and stability.

Decline in Hardware Revenue

The decline in hardware revenue suggests potential market share loss or product obsolescence, which could weaken overall revenue growth prospects.

Xtant Medical Holdings Business Overview & Revenue Model

Company Description

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.

How the Company Makes Money

Xtant Medical generates revenue primarily through the sale of its spinal and cranial surgical products. The company's key revenue streams include direct sales of medical devices to hospitals and surgical centers, as well as distribution agreements with third-party partners. Additionally, Xtant Medical may benefit from recurring revenue through the sale of biologics and other complementary products used in surgical procedures. Significant partnerships with healthcare institutions and a focus on innovation in product development contribute to the company's earnings by expanding its market reach and enhancing its product offerings.

Xtant Medical Holdings Financial Statement Overview

Summary

Xtant Medical Holdings is experiencing moderate revenue growth but faces significant challenges in profitability and cash flow. The company has improved its debt management, yet negative return on equity and cash flow issues suggest ongoing financial instability.

Income Statement

Xtant Medical Holdings shows a moderate revenue growth rate of 4.47% TTM, indicating some positive momentum. However, the company struggles with profitability, as evidenced by a negative net profit margin of -3.59% TTM. The gross profit margin is relatively healthy at 60.16% TTM, but the EBIT and EBITDA margins are low, suggesting operational challenges.

Balance Sheet

The company has improved its debt-to-equity ratio to 0.31 TTM, indicating better leverage management compared to previous periods. However, the return on equity remains negative at -10.12% TTM, reflecting ongoing profitability issues. The equity ratio is not explicitly calculated, but the balance sheet shows a stable equity base relative to total assets.

Cash Flow

Xtant Medical Holdings faces significant cash flow challenges, with a negative free cash flow growth rate of -69.85% TTM. The operating cash flow to net income ratio is low at 0.05 TTM, indicating limited cash generation from operations. The free cash flow to net income ratio is negative, highlighting cash flow constraints.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	127.77M	117.27M	91.30M	57.97M	55.26M	53.34M
Gross Profit	76.86M	68.22M	55.47M	32.14M	32.49M	34.39M
EBITDA	4.56M	-7.88M	5.08M	-5.43M	-2.51M	1.33M
Net Income	-4.58M	-16.45M	660.00K	-8.48M	-4.85M	-7.02M
Balance Sheet
Total Assets	103.48M	93.84M	92.61M	60.23M	54.69M	41.47M
Cash, Cash Equivalents and Short-Term Investments	6.92M	6.20M	5.71M	20.30M	18.24M	2.34M
Total Debt	14.80M	35.14M	23.56M	17.07M	16.84M	18.54M
Total Liabilities	54.98M	50.87M	41.26M	26.06M	23.81M	26.95M
Stockholders Equity	48.50M	42.96M	51.35M	34.17M	30.88M	14.51M
Cash Flow
Free Cash Flow	-2.83M	-16.01M	-10.97M	-7.11M	-1.68M	-2.28M
Operating Cash Flow	1.50M	-11.90M	-9.52M	-5.34M	439.00K	-731.00K
Investing Cash Flow	-4.04M	-3.73M	-24.78M	-1.56M	-1.89M	-1.30M
Financing Cash Flow	4.20M	16.07M	19.69M	9.02M	17.50M	-861.00K

Xtant Medical Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XTNT, the sentiment is Neutral. The current price of 0.75 is below the 20-day moving average (MA) of 0.80, above the 50-day MA of 0.71, and above the 200-day MA of 0.61, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 47.42 is Neutral, neither overbought nor oversold. The STOCH value of 20.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XTNT.

Xtant Medical Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	64 Neutral	$92.75M	11.98	4.92%	―	1.43%	-20.12%
XTNT	61 Neutral	$103.88M	-20.78	-9.80%	―	15.16%	-39.18%
APYX	58 Neutral	$148.00M	―	-172.18%	―	-1.32%	55.62%
NVNO	58 Neutral	$13.14M	-0.57	-57.19%	―	―	18.94%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VANI	44 Neutral	$104.22M	-3.41	-177.75%	―	―	4.91%
TELA	39 Underperform	$51.11M	-1.15	-676.41%	―	16.34%	34.86%

Xtant Medical Holdings Corporate Events

Xtant Medical’s Earnings Call Highlights Growth and Challenges

Xtant Medical Holdings Inc. recently held its earnings call, revealing a generally positive sentiment with notable revenue growth driven by the biologics segment. The company showcased improved margins and successful product launches, although challenges persist in the hardware segment and licensing revenue remains uncertain.

Xtant Medical Reports Strong Q2 2025 Results

Xtant Medical Holdings Inc. is a global medical technology company specializing in surgical solutions for spinal, orthopedic, and wound care disorders, focusing on the development and commercialization of orthobiologics and spinal implant systems.

Xtant Medical Reports Strong Q2 2025 Financial Results

On August 12, 2025, Xtant Medical Holdings announced its second quarter 2025 financial results, reporting a total revenue of $35.4 million, an 18% increase year-over-year. The company achieved a positive net income of $3.6 million compared to a net loss in the previous year and raised its full-year 2025 revenue guidance to $131-$135 million, reflecting an 11%-15% growth over 2024. Xtant Medical also highlighted its strategic move to sell non-core spinal implant and OUS businesses to Companion Spine for approximately $19.2 million, aiming to strengthen its balance sheet and focus on its core biologics business. The launch of OsteoFactor Pro™ and Trivium™ products further positions Xtant as a leader in orthobiologic solutions, enhancing its market presence and value for shareholders.

The most recent analyst rating on (XTNT) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Xtant Medical Holdings stock, see the XTNT Stock Forecast page.

Xtant Medical Sets 2025 Annual Meeting Date

Xtant Medical Holdings, Inc. has scheduled its 2025 Annual Meeting of Stockholders for November 7, 2025, with details to be provided in the company’s proxy statement. The change in the meeting date requires stockholders to submit proposals by August 18, 2025, to be considered for inclusion in the proxy materials, following SEC rules and the company’s bylaws.

The most recent analyst rating on (XTNT) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Xtant Medical Holdings stock, see the XTNT Stock Forecast page.